Case Study Work. The problem A country does not have a hadron therapy facility. The government has been briefed that many alternative options/designs.

Slides:



Advertisements
Similar presentations
Heavy Ion Cancer Therapy
Advertisements

MedAustron – Austrian Hadron Therapy Centre
1 First Considerations on LNF Tier2 Activity E. Vilucchi January 2006.
NPSS Field of Interest History and Discussion. 2 The fields of interest of the Society are the nuclear and plasma sciences. The Society shall devote itself.
The A, B, C’s of Developing A Successful Program Delta Nu Chapter Retreat October 29, 2005 Presented by Dwayne J. Scott.
Analysis and Control of Beam Dynamics in EMMA Kai Hock and Andy Wolski STFC PPRP Meeting, Glasgow, 24 June 2009.
Welcome! BASROC/CONFORM Open Day Daresbury May 11 th 2009 Roger Barlow, Manchester University and the Cockcroft Institute.
CIVL 202 Construction Engineering I Tutorial 1 T1Mon11:00-11:50 T2Wed09:00-09:50.
Heavy Ion Tumor Therapy
FFAG Fixed Field Alternating Gradient synchrotrons, FFAGs, combine some of the main advantages of both cyclotrons and synchrotrons:  Fixed magnetic field.
The High Intensity Proton Accelerator of the Paul Scherrer Institute.
12 Dec 2005 J. Schukraft1 ALICE USA ALICE position towards US participation EU participation in emcal Requirements Formal steps & schedule.
Joint Institute for Nuclear Research Grigori SHIRKOV Joint Institute for Nuclear Research Dubna, Russia International Intergovernmental Organization 18.
Machine Advisory Committee Review APS Upgrade Installation Plan and Schedule John Noonan November 15, 2006.
Comparison of Clinical Parameters for Proton Therapy in the United States Paige Summers, MS.
NICA INJECTOR Brief remarks on the status based on recent presentations and publications.
Expectations of Legislation Bree Collaborative Jason T. McGill, JD Executive Policy Advisor, Health Care Governor's Office (360)
Ion Programme of LHC Hans-H. Braun Miniworkshop on Machine and Physics Aspects of CLIC based future Collider Option, Ion Programme of LHC Hans-H.
The CONFORM project Roger Barlow BASROC launch 3 rd May 2007.
The FP7 Inputs for building a project proposal AN INFORMATION POINT FOR FP7 IN PALESTINE: Training Seminar of experts Nicosia, Cyprus November.
Schmitz F., Van Naemen J., Monclus M., Van Gansbeke B., Kadiata M., Ekelmans D., Moray M., Penninckx R., Goldman S. PET/Biomedical Cyclotron Unit, ULB-Hospital.
CLIC Implementation Studies Ph. Lebrun & J. Osborne CERN CLIC Collaboration Meeting addressing the Work Packages CERN, 3-4 November 2011.
FFAG Tune-stabilized, Linear-field FFAG C. Johnstone, Fermilab S. Koscielniak, TRIUMF FFAG06 Japan f Fermilab.
Global Design Effort 1 Possible Minimum Machine Studies of Central Region for 2009 Reference, ILC Minimum Machine Study Proposal V1, January 2009 ILC-EDMS.
Chapter 10 Architectural Design. Objectives After reading the chapter and reviewing the materials presented the students will be able to: Distinguish.
1 Tunnel implementations (laser straight) Central Injector complex.
Report from ILCSC Shin-ichi Kurokawa KEK ILCSC Chair GDE meeting at Frascati December 7, 2005.
FFAG F ixed F ield A lternating G radient Synchrotrons A new type of particle accelerator - with a wide variety of applications Cancer Therapy and UK Activities.
VIEW on RAD HARDNESS TESTS of STS FEE IN MEPHI. Simakov A.B. – Head of “Special Microelectronics” Lab.
TPS & Simulations within PARTNER D. Bertrand, D. Prieels Valencia, SPAIN 19 JUNE 2009.
11 November 2010 Natascha Hörmann Computing at HEPHY Evaluation 2010.
CHEE 323J.S. Parent1 Enantioselective Hydrogenation-Design Exercise #2 Despite its rather severe side-effects, L-Dopa (3,4- dihydroxyphenylalanine) is.
1 Report of PAC for Particle Physics T. Hallman Presented by P. Spillantini JINR Scientific Council Meeting June 3-4, 2004 Dubna, Russia.
Project X RD&D Plan Beam Transfer Line and Recycler Injection David Johnson AAC Meeting February 3, 2009.
Level 2 Unit 2 Investigating Engineering Design Engineering Diploma Level 2 Unit 2 Investigating Engineering Design In this unit you will find out how.
1 Future Circular Collider Study Preparatory Collaboration Board Meeting September 2014 R-D Heuer Global Future Circular Collider (FCC) Study Goals and.
ENLIGHT,12/2/20021 Health and Science, can CERN contribute? The Mission of CERN (1954): “The Organization shall provide for collaboration among European.
SECONDARY-BEAM PRODUCTION: PROTONS VERSUS HEAVY IONS A. Kelić, S. Lukić, M. V. Ricciardi, K.-H. Schmidt GSI, Darmstadt, Germany  Present knowledge on.
Evaluating Emerging Technologies: Is the Future Now?? Elise Berliner, PhD Director, Technology Assessment Program Center for Outcomes and Evidence.
ILC 2007 Global Design Effort 1 Planning Damping Rings Activities in the Engineering Design Phase Andy Wolski Cockcroft Institute/University of Liverpool.
T. Fleck, GSI, Darmstadt, Germany ICALEPCS Status of the Control System for HICAT at an advanced stage of Commissioning Functions, Restrictions.
1 The next steps – focusing points Define the scope, strategy and cost of the project implementation. Main input: The evolution of the physics findings.
JINR-CERN 5-years Partnership Program N.Russakovich 103-rd session of theJINR Scientific Council meeting JINR, Dubna, 21 February 2008.
Proposal for ESS DTL Roadmap. Divide Into Four Phases 1.Conceptual Design Phase (In progress) 2.Technical Design Phase 3.Prototyping Phase 4.Construction.
Proton Driver Keith Gollwitzer Accelerator Division Fermilab MAP Collaboration Meeting June 20, 2013.
Bad Zurzach, 1-4 December 2014 Stéphane Sanfilippo p. 1 Stéphane Sanfilippo, Paul Scherrer Institut Accelerator activities at PSI Wir schaffen Wissen –
Introduction to NS-FFAGs and EMMA Rob Edgecock STFC Rutherford Appleton Laboratory.
A. FaccoEURISOL DS Orsay, 3 Feb 2005 Task 7 Proton Accelerator “The objective of the Proton Accelerator Task is the design a 5 mA CW, 1 GeV proton linac.
Contract: EIE/07/069/SI Duration: October 2007 – March 2010Version: July 7, 2009 Ventilation for buildings Energy performance of buildings Guidelines.
Alternative Methods for Production of Ac225 James Harvey 1, Jerry A. Nolen 3, Thomas Kroc 4, Itacil Gomes 5, E. Philip. Horwitz 2, Daniel R. McAlister.
Wir schaffen Wissen – heute für morgen Paul Scherrer Institut Introduction du PSI Workshop Precision Particle Physics Prof. Dr Joël Mesot.
MAC meeting (12-13 January 2010) Machine Advisory Committee participants: B.Sharkov (ITEP/FAIR) P.Belochitskii (CERN) S.Ivanov (IHEP, Protvino) M.Steck.
April 17, Dejan TrbojevicFFAG07 -Non-Scaling FFAG gantries1 Non-Scaling FFAG Gantries Introduction: Motives: The most challenging problem in the carbon/proton.
FNAL SCRF Review R. Kephart. What is this Review? FNAL has argued that SCRF technology is an “enabling” accelerator technology (much like superconducting.
Clinical Practice Improvement (CPI)
Comprehensive, Collaborative System of Crisis and Emergency Care
Progress in the Application
Highlights from INFN-MED
WP9-SuperB in TIARA M. Biagini, INFN-LNF.
MSc-Student Activities at the European XFEL
Radiopharmaceutical Production
PROGRESS REPORT OF A NLNS-FFAG ADS MAGNET
PROJECT TITLE Hook -Describe your final product and bussiness idea
Science parks and technological support at ELI Beamlines
HST Medical Applications
Measurements, ideas, curiosities
ADS Accelerator Program in China
HEALTHCARE INNOVATION FORUM 2018
Possibilità di tesi presso il CNAO
MEIC Cost Estimate Overview
Presentation transcript:

Case Study Work

The problem A country does not have a hadron therapy facility. The government has been briefed that many alternative options/designs can be considered. You have been requested to consider the possible alternatives, choose one and produce a preliminary study.

The task You shall first of all decide which particle species the proposed facility shall provide and explain the reasons of your choice. Non-clinical reasons can also be considered like "establishing an accelerator community for the future creation of other research facilities" or "part of the beam time will be used for non clinical research". A few alternative designs between those proposed in literature shall be considered and compared. Finally one type of center shall be chosen and a baseline design shall be carried out.

Aspects to describe Assumptions on the number of patients per year, time dedicated to treatments, QA, machine development and maintenance. Assumed number of fractions, number of fields per fraction, time needed for patient handling. Overall design parameters – Beam energies, intensity, spot size. Beam delivery system(s) Technical specification – Source, injectors, accelerator, extraction systems, transfer lines An idea of the expertise needed to build and operate the facility Time scale for construction, accelerator commissioning, clinical beam qualification, clinical trials Cost estimate, reimbursement fees, running cost, yearly income. Limitations of the facility

Working groups

Group 1 ValentinaBellinzonaUniversity of Pavia Jose LuisAbelleira FernandezCERN AlexanderWastlMedAustron DanielAdjeiInstitute of Optoelectronics NawinJuntongSynchrotron Light Research Institute ChristianSchoemersHIT Group 2 JennyDueckPSI SejlaMizic-BajricMedAustron MichaelBodendorferCERN StefanoBenedettiCERN EPFL - TERA Foundation LuisMora VallejoCERN XanderJanssenVDL ETG Research ViktorIakovenkoKiev Institute for Nuclear Research

Group 3 MarenEberhardtVarian Medical Systems EvgeniiaSukhikhTomsk Polytechnik University JoseSanches AriasMedAustron GhislainRoyCERN JoachimWallnerMedAustron PoompisPattaranutapornMahidol University Group 4 JasonWuZion Biotech SophieSeidelHelmholtz Zentrum Berlin DamienPerreletCERN OliverTrieblMedAustron MathiasEichingerMedAustron YuliaKluchevskayaNRNU MEPhI

Group 5 EvelinaJaselkyteHospital of Lithuania RobertoLopezCERN SebastianBrachtGSI SebastienPelletierMedAustron StefanoPioliUniversity of Rome "La Sapienza" MarkusStrohmeierMarburg Ion beam Therapy Center Group 6 JasnaJunuzovicMedAustron MartinaSenzacquaUniversita' degli studi di Roma, La Sapienza AlexandreLasheenCERN JuanEsteban MullerCERN/EPFL MatthiasKronbergerMedAustron AnthonyHugginsVarian Medical Systems Particle Therapy JukkaJaatinenUniversity of Jyvaskyla

Group 7 AdrianaRossiCERN JorgeGiner NavarroCERN MohammedAlmalkiGSI ChristophKurfuerstMedAustron LucaSabatoUniversity of Sannio JarnoAlaraudanjokiUniversity of Jyvaskyla Group 8 MarynaKanapelkaJIPNR ConcepcionOliverCIEMAT MarcoGarlascheCERN TobiasStadlbauerMedAustron RupertLangeggerMedAustron YuanXuPeking University

Group 9 SamPitmanThe Cockcroft Institute BenjaminKoubekCERN Jose MPerezCIEMAT MatjazRepovzMedAustron ManuelFuertingerMedAustron MarcoEspositoADAM SA Group 10 WiolettaKozlowskaCERN KatarinaSedlackovaSlovak University of Technology StefanSchwarzMedAustron Ricardo Manueldos Santos AugustoCERN ClausSchmitzerMedAustron ManuelBennaVarian Medical Systems DominikPeruskoCosylab D.D.

Group 11 HanLiUppsala University ValeriaRizzoglioPaul Scherrer Institut Jamesdela CruzCanadian Light Source Inc. VelikoDimovCERN MauroPiviMedAustron SebastianRotheCERN Group 12 ValeriaLanteCNAO SilviaSchuhCERN IlyaAshanin NRNU MEPhI BasilGonsalvesCERN PatricioNadigMedAustron JeromeSchwindlingCEA Saclay ClaudeKrantz